Barclays Maintains Overweight on Medline, Lowers Price Target to $45

Benzinga Newsdesk www.benzinga.com Negative 88.9%

Neg 88.9% Neu 0% Pos 0%

Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $50 to $45.